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Background: The fraction of nitric oxide in exhaled air (FeNO) is used in asthma diagnosis and
management. Smoking reduces FeNO and 20e35% of asthmatics are smoking. However no
guidelines exist on the diagnostic value of FeNO in smokers. Therefore we assessed the value
of FeNO to diagnose asthma in a population of subjects with asthma-like symptoms and
different smoking habits.
Methods: Measurements of FeNO, lung function, bronchial responsiveness and allergy testing
were performed in 282 subjects (108 never-, 62 ex- and 112 current smokers) aged 14e44
years, with symptoms suggestive of asthma. These subjects were a subset of subjects reporting
respiratory symptoms (n Z 686) in a random population sample (n Z 10,400).
Results: A diagnosis of asthma was given to 96 of the 282 subjects. Subjects with asthma had
higher FeNO levels than subjects with non-specific asthma symptoms in all three smoking
strata (p < 0.001), with a percentual increase of FeNO by 76% in never-, 71% in ex- and 60%
in current smokers. The area under the ROC-curve was similar in never-, ex- and current
smokers (0.72 vs. 0.74 vs. 0.70). The cut-offs were approximately 30% lower for either 90%
specificity (22 vs. 31 ppb) or 90% sensitivity (7 vs. 10 ppb) in current vs. never-smokers.
Conclusions: FeNO could differentiate asthmatic subjects from non-asthmatic subjects with
asthma-like symptoms equally well in both never- and current smokers within a random popu-
lation sample. The FeNO cut-off levels needed in order to achieve high sensitivity or specificity
were lower in current smokers.
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The fraction of nitric oxide in exhaled air (FeNO) is
a marker of steroid-sensitive airway inflammation, used in
monitoring the treatment of patients with asthma.1
However, the diagnostic value of exhaled NO for asthma
is still debated and is more modest in the general pop-
ulations2 than in subjects with symptoms highly suggestive
of asthma.3,4 Different optimal FeNO cut-offs for diagnosing
asthma have been reported in different studies.5 The
general recommendations, also reiterated by the recently
published ATS Clinical Practice Guideline, are that a FeNO-
value below 25 ppb, measured at a exhaled flow-rate of
50 mL/s, suggests that there is no steroid-sensitive
inflammation present, while a value greater than 50 ppb
is likely to be associated with steroid-sensitive inflamma-
tion.1,6,7 These cut-offs have been described for adult non-
smoking subjects and although it is well acknowledged that
smoking reduces FeNO both in healthy and asthmatic sub-
jects,8e12 no clear guidelines exist for the use of exhaled
NO in smoking asthmatics1,6,7,13, indicating a need for more
knowledge in this field.
Smoking asthmatics are a category of patients repre-
senting up to 20e35% of the adult asthma patients in
Northern Europe.14,15 Smoking induces a decrease of
exhaled NO levels in both healthy8,9 and asthmatic
subjects.10,11 In epidemiological studies, this decrease in
FeNO has been reported to be in the range 30e60% when
compared with FeNO-values of never-smoking sub-
jects.16e18 Several mechanisms, such as an inhibited bron-
chial epithelial iNOS-related production of NO19,20 or an
increased catabolism of NO,21 have been postulated to
explain this decrease. The clinical use of exhaled NO in
smoking asthmatic subjects has been questioned, as a more
neutrophil- and steroid-insensitive inflammation has been
described in smoking asthmatics.22 Contradictory results
are reported regarding the presence of increased levels of
exhaled NO in asthmatic smokers compared with healthy
smokers.23e25 Furthermore, the effects of previous smoking
on exhaled NO are controversial with a slight decrease16 or
no decrease17 in FeNO. No study has addressed the value of
exhaled NO in diagnosing asthma in ex-smoking subjects.
A problem with the previous studies2,23e25 looking at the
diagnostic value of FeNO in current smokers is that the
reference group consisted of healthy smokers. However, in
clinical practice the need is in differentiating subjects with
asthma-like symptoms that have asthma diagnosed from
the ones that do not have asthma. Therefore, the aim of
the present study was to assess the value of exhaled NO to
diagnose asthma in a population of subjects with asthma-
like symptoms, with special emphasis on the value of
exhaled NO to diagnose asthma in subjects with different
smoking habits.
Methods
Screening population
A random population sample of 10,400 subjects, aged
14e44 years, and living in Denmark was drawn from the
civil registration list,26 with the aim of examining asthmatreatment in a Western society. All subjects were mailed
a letter with a validated self-administered asthma and
rhinitis screening questionnaire including 20 questions
adopted from the ACAAI screening program.27 Of the 47%
that responded, 2250 had at least one respiratory and/or
nasal symptom. 686 of these subjects recorded two or more
respiratory symptoms, accepted the study invitation and
were examined.
Examination
All participants had their lung function measured (Vital-
ograph), and a specific IgE test was performed, followed
by a bronchial provocation test with methacholine and
a reversibility test with inhaled beta2-agonist, as previously
described elsewhere.26 Halfway through the study it
became possible to measure exhaled NO, after which these
measurements were performed on 320 of 329 (97%) of the
participants. Exhaled NO (FeNO) was measured using an
online technique at a exhalation flow-rate of 50 mL/s,
based on electrochemical sensor (NIOX Mino, Aerocrine AB,
Solna, Sweden), according to ATS guidelines.28 The
measurements of exhaled NO were performed at approxi-
mately 1 h after the start of examination and before any
lung function tests.
Exclusion and inclusion criteria
Subjects with at least two symptoms suggestive of asthma
(listed in the Online Supplement Table S1) were eligible for
the present study and therefore 33 subjects with no
symptoms when examined at the clinic or only one asth-
matic symptom were excluded. Subjects fulfilling the
spirometric criteria for COPD were excluded (n Z 5),
leaving a total of 282 subjects included in the study.
Smoking history
All participants filled in a questionnaire regarding smoking
habits. Subjects were classified as never-smokers, ex-
smokers (subjects who ever have smoked or tried smoking)
and current smokers (subjects currently smoking). Life-
time tobacco exposure was calculated for ex- and current
smokers as pack-years (tobacco consumption [cigarettes/
day]/20 * duration of smoking [years]).
Asthma diagnosis
All subjects were interviewed by a respiratory specialist
(70% of the cases the same specialist), who made a diag-
nosis of asthma based on the presence of symptoms of
asthma (i.e. shortness of breath, chest tightness, cough,
exercise induced dyspnoea, night-time awakenings, or
respiratory symptoms induced by allergen contact) in
combination with at least one of the following:
1) Airway hyper-responsiveness (AHR) to inhaled
methacholine < 8.0 mmol.
2) At least 250 ml increase in FEV1 after bronchodilator.
29
3) Daily use of systemic steroid, inhaled steroid, or
inhaled beta2-agonist.
796 A. Malinovschi et al.4) Asthma symptoms during but not outside the pollen
season, eventually supported by allergic rhinitis,
although no objective signs of asthma outside season
were found.
Diagnosis of rhinitis
Patients with rhinitis were defined as subjects with symp-
toms of rhinitis such as runny nose, stuffy nose, sneeze,
itchy nose, mouth, ear or eyes, red and runny eyes,
reduced sense of smell, or symptoms due to allergen
exposure.
Statistical analysis
STATA version 10.1 (Stata Corp, College Station, TX, USA)
was used for all analyses.
The distribution of FeNO levels is skewed to the right
and therefore log-transformation was used in order to meet
normality assumptions. Similarly, methacholine dose-
response slope (DRS) and blood eosinophils were log-
transformed as they are known to have a similar distribution
as FeNO.Consequently, FeNO,DRSandbloodeosinophilswere
presented as geometrical mean (95% CI) in descriptive statis-
tics. Percentual increase of FeNO in asthmatic subjects vs.
non-asthmatic subjects was obtained from linear regression
models before and after adjusting for other known determi-
nants of FeNO (sex, height, age, airway calibre (FEV1(%pred)),
use of inhaled corticosteroids andpollen season30) after back-
transformation of regression coefficients, as previously
described elsewhere.23 The optimal cut-off for theTable 1 Subject characteristics expressed as mean (standard
confidence interval (95% CI).
Non-specific asthm
symptoms (n Z 18
Age (mean (SD)) 32.7 (8.9)
Female gender (N(%)) 112 (60.2%)
IgE-sensitisation (N(%)) 40 (22.0%)
Blood eosinophils (GM(95%CI)) 0.17 (0.16, 0.19)
Smoking history
Never (N(%)) 63 (33.9%)
Ex (N(%)) 43 (23.1%)
Current (N(%)) 80 (43.0%)
Rhinitis (N(%)) 86 (46.2%)
FEV1% pred (mean (SD)) 97.0 (10.8)
FVC% pred (mean (SD)) 96.8 (11.5)
FEV1/FVC (mean (SD)) 0.82 (0.07)
AHR (N(%)) 4 (2.2%)a
DRS (GM(95%CI)) 0.65 (0.59, 0.71)a
SABA-use (N(%)) 3 (1.6%)
ICS-use (N(%)) 1 (0.5%)
Asthma symptomsb 4 (3, 6)
Abbreviations: FEV1 e forced expiratory volume in 1 s, FVC eforced vit
methacholine < 8 mmol), DRS e dose-response slope to methacholi
corticosteroids.
a Two subjects in the non-specific asthma symptoms group and sev
provocation test.
b Expressed as median (interquantile range).ROC-curves was defined as corresponding to the maximum
value of Youden’s index (sensitivity þ specificity - 1).31Ethics
The study was approved by the Ethics Committee of Aal-
borg, Denmark. All participants received information in
both oral and written forms and gave their consent in
writing before enrolment.Results
Population characteristics with regard to asthma
diagnosis
The subjects who underwent FeNO measurements did not
differ from the other participants undergoing clinical
examination in terms of any of the variables presented in
Table 1 (all p-values > 0.05, data not shown), apart from
the percentage of asthma patients, which was smaller then
found in the group that did not have FeNO measured (33% vs
46%, p Z 0.01).
The characteristics of the subjects included in the present
study are shown, with regard to final diagnosis, in Table 1.
Subjects who were diagnosed with asthma were more often
IgE-sensitised, had rhinitis, and used inhaled corticosteroids
or bronchodilators more frequently, compared with subjects
with symptoms that were concluded to be non-specific.
Furthermore, asthmatic subjects had a higher degree ofdeviation(SD)), N(%) or geometrical mean (GM) with 95%
a
6)
Asthma (n Z 96) p-value
32.7 (8.7) 1.00
57 (59.4%) 0.89
50 (54.4%) <0.001
0.21 (0.19, 0.24) 0.002
45 (46.9%) 0.10
19 (19.8%)
32 (33.3%)
63 (65.6%) 0.002
94.4 (15.2) 0.11
97.2 (12.8) 0.82
0.80 (0.09) 0.01
35 (36.5%)a <0.001
1.65 (1.30,2.08)a <0.001
46 (47.9%) <0.001
24 (25.2%) <0.001
6 (4, 8) 0.02
al capacity, AHR e airway hyper-responsiveness (defined as a PD20
ne provocation, SABA - short-acting beta2-agonist, ICS - inhaled
en subjects in the asthma group did not perform methacholine
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eosinophils and had a lower FEV1/FVC-ratio (Table 1).
The pack-year consumption in the currently smoking
group (n Z 112) was 10 (0, 30) (median, range) and 14
subjects had a pack-year consumption < 1. The ex-smoking
group (n Z 62) was characterised by a pack-year
consumption of 0 (0, 7.5) and 50 subjects had a pack-year
consumption < 1. Atopy was less common in subjects who
were current smokers than never- or ex-smokers (22% vs.
46% and 48%, respectively).Exhaled NO and smoking habits
The FeNO-values were significantly lower in the currently
smoking group (11.9 ppb (10.5, 13.5)) than in the never-
smoking group (17.6 ppb (15.2, 20.2), p < 0.001) and the
ex-smoking group (18.0 ppb (15.6, 20.8), p < 0.001). No
significant differences between never- and ex-smoking
subjects were found in regard to FeNO.Using FeNO to differentiate asthma from non-
specific asthma symptoms
Subjects with asthma had higher levels of exhaled NO than
subjects with non-specific asthma symptoms (21.8 ppb
(18.6, 25.5) vs. 12.5 ppb (11.5, 13.6), p < 0.001). The area
under the curve (AUC) for the ROC of FeNO for asthma
diagnosis was 0.72 (0.66, 0.79). The value was similar after
excluding the subjects currently using inhaled corticoste-
roids (AUC 0.73 (0.65, 0.80), n Z 256).
Subjects with asthma had higher FeNO levels than
subjects with non-specific asthma symptoms in all three
smoking strata (p < 0.001, Table 2) with a percentual
increase of FeNO of 76% in never-, 71% in ex- and 60% in
current smokers (Fig. 1A). Even after adjustments for
potential confounders as sex, height, age, airway calibre
(FEV1(%pred)), use of inhaled corticosteroids and pollenFigure 1 Percentual increase (mean (95%CI)) of FeNO in asthmati
smoking history before (panel A) and after adjustments for sex, h
costeroids, pollen season (panel B).season, increased exhaled NO was significantly related to
presence of asthma (Fig. 1B).
ROC-curves for the value of exhaled NO to detect
asthma in never-, ex- and current smokers are presented in
Fig. 2.
The areas under the ROC-curves, optimal cut-offs and
cut-offs for 90% sensitivity and 90% specificity for FeNO
levels to diagnose asthma are presented in Table 3. No
significant differences between the AUC-values for the
ROC-curves of FeNO were found between the three smoking
strata (p > 0.05). The AUC for the ROC-curve for current
smokers, after excluding smokers with a pack-year history
less than 1 pack-year, was unchanged (0.70 (0.57, 0.82),
nZ 98) as were the cut-offs for 90% sensitivity (6 ppb), 90%
specificity (22 ppb) and optimal cut-off (17 ppb).
Excluding subjects on inhaled corticosteroids, the AUC
values were 0.76 (0.65, 0.86) for never-smokers (n Z 96),
0.74 (0.55, 0.93) for ex-smokers (n Z 55) and 0.68 (0.56,
0.81) for current smokers (n Z 105). No significant differ-
ences between the AUC-values for the ROC-curves in the
three smoking strata were found (p > 0.05). The cut-offs
for 90% sensitivity were 11 ppb (spec 33.9%), 11 ppb (spec
23.3%) and 6 ppb (spec 20%) in never-, ex- and current
smokers. The cut-offs for 90% specificity were 31 ppb (sens
41.2%), 26 ppb (sens 41.7%) and 22 ppb (sens 36%) in never-,
ex- and current smokers.
In Table 4, the sensitivity and specificity at different
FeNO cut-off levels are given. Positive predictive values
and negative predictive values for these arbitrary cut-offs
are presented in Online Supplement Table S2.Exhaled NO and its relationship to atopy, bronchial
responsiveness and blood eosinophils in the
different smoking strata
There was a positive association between bronchial
responsiveness and exhaled nitric oxide among never-cs vs. subjects with non-specific asthma symptoms in relation to
eight, age, airway calibre (FEV1(%pred)), use of inhaled corti-
Table 2 Levels of FeNO (GM(95%CI)) in subjects with non-specific asthma symptoms or asthma in different smoking strata.
Non-specific asthma symptoms (n Z 186) Asthma (n Z 96) p-value
Never-smokers 13.9 (12.0, 16.0) (n Z 63) 24.4 (19.0, 31.3) (n Z 45) <0.001
Ex-smokers 15.3 (13.5, 17.4) (n Z 43) 26.1 (18.9, 36.1) (n Z 19) <0.001
Current smokers 10.4 (9.1, 11.9) (n Z 80) 16.7 (12.8, 21.7) (n Z 32) <0.001
798 A. Malinovschi et al.(r Z 0.39, p < 0.001), ex- (r Z 0.40, p Z 0.002) and
current smokers (r Z 0.36, p < 0.001).
A positive association was found between exhaled NO
levels and presence of atopy in all three smoking strata
(p < 0.001) as well as between FeNO levels and blood
eosinophil levels in never- (rZ 0.45, p < 0.001) and current
smokers (r Z 0.31, p Z 0.001).Discussion
The main finding of the present study was that exhaled
nitric oxide could differentiate asthmatic subjects from
non-asthmatic subjects equally well in both the never- and
current smoker strata within a population with asthma-like
symptoms. The FeNO cut-off levels needed in order to
achieve high sensitivity or specificity for asthma diagnosis
were thus lower in current smokers. However, the per-
centual asthma-associated increase of FeNO was of
a similar size in currently smoking and in never- or ex-
smoking subjects.
The main strength of this study is that the present
selection of the subjects corresponds to a primary care
setting where subjects would seek for their asthma-like
respiratory symptoms. The relatively even distribution of
this population with regard to smoking history and the
majority of the assessments being performed by the same
nursing staff are other strengths of the study. We
acknowledge however the low life-time tobacco consump-
tion in this group of young adults, especially in the ex-
smoking group, that might have an impact on generalisation
of present results. A weakness of this type of study, where
patients are asked to participate via questionnaire, is that
subjects with milder symptoms might not participate.
However, this would not have affected the clinical impor-
tance of the present results, as these patients would
probably not seek medical care for their symptoms anyway.
In this study performed in 2005e2006, FeNO measurementsFigure 2 ROC-curve for the diagnostic value of exhaled NO to pr
panel) and currently smoking (right panel) subjects with asthma liwere commenced halfway through the study and as all
participants were invited simultaneously to participate, it
is plausible to believe that asthma patients would respond
faster, and hence be among the first to be tested. We
cannot precisely know how this difference in the proportion
of asthmatics tested affects the estimates of sensitivity and
specificity, but it is unlikely that the effect is different for
smokers vs non-smokers.
Exhaled NO discriminated between asthmatics and non-
asthmatics in all the three smoking strata. That exhaled
NO can differentiate asthmatics from non-asthmatics in
never-smokers is well-known.1,32 The discriminatory value
in currently smoking individuals was however questioned in
previous studies17,23,33 and mechanistically explained by a
predominant neutrophilic22 or paucigranulocytic34 inflam-
mation of the airways in smoking asthmatics, which is not
accompanied by increased FeNO. This is however not sup-
ported by a recent study that demonstrated a reduction of
bronchial production of NO in response to oral steroids in
smoking asthmatics, giving support for presence of eosino-
phil, steroid-sensitive inflammation in the airways of
smoking asthmatic subjects.35 Moreover, similar levels of
sputum eosinophils, as well as similar predictive value of
FeNO for detecting sputum eosinophilia were found in
smoking and non-smoking asthmatics.36 Similarly, in the
present material we could show similar relations between
FeNO and blood eosinophils in both current and never-
smoking strata. Rouhos et al.25 and Matsunaga et al.37
reported higher levels of exhaled NO in asthmatic smokers
than in healthy smoking subjects, results in line with the
present study. One major difference between these studies
and our study is the fact that the controls in our study were
also subjects with asthma-like symptoms and not healthy
subjects without any lower respiratory symptoms, which
probably explains the lower discriminative value of the
FeNO in the present study compared with in Matsunaga
et al.37 This study design difference makes the results
of the present study more relevant in the clinical setting.edict asthma in a population of never- (left panel), ex- (middle
ke-symptoms.
Table 3 Description of AUC and three chosen cut-offs (optimal, 90% sensitivity and 90% specificity) for ROC-curves presented
in Fig. 2.
Never-smokers (n Z 108) Ex-smokers (n Z 62) Current smokers (n Z 112)
Number of asthma cases 45 19 32
AUC 0.72 (0.62, 0.82) 0.74 (0.60, 0.89) 0.70 (0.59, 0.82)
Optimal cut-off 15 ppb 22 ppb 17 ppb
(sensitivity, specificity) (77.8%, 63.5%) (63.2%, 86.1%) (56.3%, 82.5%)
(PPV, NPV at this cut-off) (60%, 80%) (67%, 84%) (57%, 82%)
Cut-off for 90% sensitivity 10 ppb 11 ppb 7 ppb
(specificity at this cut-off) 26.9% 23.3% 15.1%
(PPV, NPV at this cut-off) 47%, 81% 36%, 91% 32%, 89%
Cut-off for 90% specificity 31 ppb 26 ppb 22 ppb
(sensitivity at this cut-off) 35.6% 42.1% 37.5%
(PPV, NPV at this cut-off) 72%, 66% 65%, 78% 61%, 78%
Abbreviations: AUC e area under the curve, ROC e receiver operating characteristic, PPV e positive predictive value, NPV e negative
predictive value.
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never-smoking subjects. It might have been expected that
this group would show a discrepancy between symptoms
and inflammation as an improvement of symptoms with
continuing oxidant and protease burden has been reported
by Louhelainen et al.38 On the other hand, the epithelial
changes seen in smoking asthmatics are not found in ex-
smoking asthmatics, suggesting that at least these
changes can be reversed by smoking cessation. Regarding
exhaled NO, the effects of previous smoking have previ-
ously been considered transitory,39 and the effects of ex-
smoking in populational studies has been contradictory,
with a decrease of about 10% in some studies16,40 and no
clear effect in other studies.17 In the present population of
young adults, the large majority of ex-smokers had a very
low life-time tobacco consumption, which may also explain
why no significant differences in the levels of exhaled NO
were found.
An important finding of the present study was that FeNO
cut-off levels needed in order to achieve either high spec-
ificity or sensitivity were lower in current than never-
smokers. We proposed a cut-off of 22 ppb in current
smokers vs. 31 ppb in never-smokers for 90% specificity.
These levels correspond to an approximately 30% lower cut-
off in current smokers, results in line with the proposed
best cut-offs by Matsunaga et al.37 or Schleich et al.36 The
magnitude of decrease of FeNO cut-off levels in current vs.Table 4 Sensitivity and specificity for different arbitrary FeNO
FeNO cut-off Never-smokers (n Z 108) Ex-sm
Sensitivity Specificity Sensit
10 91% 27% 95%
15 78% 64% 80%
20 51% 82% 68%
25 40% 89% 42%
30 35% 90% 42%
35 27% 94% 37%
50 20% 95% 16%never-smokers corresponds to reported smoking-induced
decrease of FeNO (30e60%) in population-based
materials.16e18
Different optimal FeNO cut-offs to diagnose asthma have
been reported in the literature, as summarized by Majid
et al.5 Defining the optimal cut-off by maximising the sum
of sensitivity and specificity resulted in a higher cut-off for
current smokers than for never-smokers in the present
material, as opposed to an expected lower cut-off, which
was the case for the cut-offs for 90% sensitivity or speci-
ficity. This underlines the weakness of presenting only
optimal cut-offs. An approach of the type rule-in/rule-out
has been suggested, with a FeNO-value < 25 ppb in order
to exclude the presence of steroid-sensitive asthmatic
inflammation and value > 50 ppb to signal the presence of
steroid-sensitive asthmatic inflammation.1,6,7 Looking at
the present material, it must be underlined that the high
sensitivity (90%) necessary to rule out was obtained only at
very low levels of FeNO, under 10 ppb. These cut-offs were
also associated with a good negative predictive value of
around 80% in never-smokers and 90% in ex- and current
smokers. A value of FeNO > 25 ppb in never- and ex-
smokers was associated with values of specificity around
90% in all three groups. However, in the current-smoking
group this cut-off was too high and resulted in a lower
sensitivity compared with never- and ex-smokers. The
achieved positive predictive values were more modest incut-offs in the range 10e50 ppb in different smoking strata.
okers (n Z 62) Current smokers (n Z 112)
ivity Specificity Sensitivity Specificity
16% 78% 48%
47% 56% 73%
74% 44% 88%
91% 25% 93%
95% 19% 94%
98% 16% 96%
98% 9% 98%
800 A. Malinovschi et al.the current-smoking group and the best PPV-values were
77% in never-smokers and 89% in ex-smokers, both for a cut-
off of 35 ppb.
In conclusion, the present study offers support for the
use of exhaled NO for diagnosing asthma in subjects with
asthma-like symptoms even if they are ex-smokers or
current smokers, as the diagnostic value of exhaled NO for
asthma was similar in all three examined smoking strata.
For both smokers and non-smokers, there was a clear
separation in FeNO-values between asthmatics and non-
asthmatics. The different cut-off values shown in this
article as necessary in order to achieve higher sensitivity or
specificity should offer decision support for the clinician
dealing with the interpretation of the test in patients with
asthma-like symptoms who have previously smoked or are
still smoking. These FeNO cut-off values should be further
validated in other studies, and in particular, there is a need
for studies documenting these cut-offs in relation to
measures of eosinophilic airway inflammation or response
to steroid treatment, in order to evaluate their ability to
rule in or rule out the presence of steroid-sensitive airway
inflammation in smokers.
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